IUGNF - Imugene Limited
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.0779 |
| Open | 0.0750 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0735 - 0.0750 |
| 52 Week Range | 0.0729 - 0.2126 |
| Volume | |
| Avg. Volume | 126,743 |
| Market Cap | 475.305M |
| Beta (5Y Monthly) | 2.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
News DirectImugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial
Imugene Ltd (ASX:IMU) CEO Leslie Chong tells Proactive that the company has dosed the first patients in cohort three of its intravenous (IV) and intratumoral (IT) monotherapy dose-escalation trial ...
News DirectImugene thrilled as first patients dosed in VAXINIA MAST combination study
Imugene Limited (ASX: IMU) CEO Leslie Chong tells Proactive the company’s Phase 1 MAST (metastatic advanced solid tumours) study evaluating the safety of novel cancer-killing virus CF33-hNIS (VAXIN...
GlobeNewswireCelularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates
Commercial Biomaterials Business, Degenerative Disease Programs Continue to Gather Momentum Animal and Preclinical Data Support Significant Opportunities in Osteoarthritis for Biomaterial-Cell Therapy Combination Approach FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” the “Company”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial-based regenerative therapeutics products, announced today
News DirectImugene off to strong start to 2023 with JP Morgan Healthcare Conference
Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive it has been a busy and productive start to the new year with a number of presentations including at the JP Morgan Healthcare Confer...
GlobeNewswireImugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company and Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, are pleased to announce that data from preclinical studies of Imugene’s onCARlytics (CF33-CD19) oncolytic virus in combination with Celularity’s placental-derived off-the-shelf allogeneic
- GlobeNewswire
Diamond Equity Research Initiates Coverage on Imugene Ltd. (ASX: IMU)
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Imugene Ltd. (ASX: IMU). The in-depth 31-page initiation report includes detailed information on the Imugene’s business model, services, industry, valuation, management, and risks. The full research report is available here. Highlights from the report include: Diversified Pipeline with Multiple Candidates in Clinical
Simply Wall St.Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...